若生智能
Drug Database
UR

urokinase (Breokinase / Alphakinase / Thrombolase)

✓ Approved

Mitsubishi Tanabe Pharma Corporation · PLAU

什么是 urokinase？

urokinase 是一种治疗药物，由Mitsubishi Tanabe Pharma Corporation研发。该药已获批，用于治疗相关适应症。

药物档案

商品名Breokinase, Alphakinase, Thrombolase
公司Mitsubishi Tanabe Pharma Corporation
分子靶点PLAU
状态Approved
来源： ClinicalTrials.gov, Mitsubishi Tanabe Pharma Corporation

作用机制

分子靶点

urokinase 作用于 1 个分子靶点：

PLAUplasminogen activator, urokinase (URK, UPA)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

urokinase 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Respiratory, thoracic and mediastinal disordersPulmonary thrombosis✓ Approved

相关研究文献

PubMedExperimental cell research2026-06-10

Functional analysis of uPAR alternatively spliced isoforms.

Kulíšková Petra P, Zapletal Ondřej O, Ballonová Lucie L, Kocourková Anna A et al.

The urokinase-type plasminogen activator receptor (uPAR) plays an essential role in cellular adhesion, migration, and differentiation. Alternative splicing of the PLAUR gene generates several isoforms, including ΔE5 and ΔE6, whose biological functions remain unclear. This study examined the localization and functional properties of these variants in comparison with membrane-bound uPAR (muPAR). Although ΔE5 and ΔE6 retain an intact GPI-anchor sequence, both isoforms were intracellularly retained and failed to localize to the cell membrane, unlike muPAR. In PMA-induced differentiation assays, only muPAR-expressing cells maintained adhesion after stimulation, whereas ΔE5, ΔE6, and PLAUR-/- cells did not. All cell lines expressed the macrophage differentiation marker SR-A I, indicating preserved differentiation capacity. Functional analyses showed that only muPAR-expressing cells adhered to vitronectin and interacted with α5β1 integrin. Neither ΔE5 nor ΔE6 bound vitronectin, even after PMA or uPA stimulation, nor did they interact with α5β1 integrin. Functionally, both variants closely resembled uPAR-deficient cells. These results demonstrate that exons 5 and 6 are critical for proper uPAR localization and function. Dysregulated PLAUR splicing may therefore contribute to pathological processes, and modulation of uPAR splicing could represent a potential therapeutic approach.

PMID 42264119
阅读全文 →
PubMedBiomarker insights2026-06-08

Insight to Neglected Biomarkers in COVID-19: A Comprehensive Narrative Review".

Jalilian Shahram S, Bastani Mohammad-Navid MN, Afsharzadeh Fatemeh F

In the context of COVID-19, a range of neglected biomarkers provide critical insights into the mechanisms of the disease and potential therapeutic targets. This review aims to address this gap by systematically analyzing the diagnostic and prognostic potential of these neglected biomarkers, with particular emphasis on their mechanistic connections to COVID-19 pathophysiology. Reduced levels of adiponectin and prostacyclin (PGI2) and elevated level of endothelin are associated with endothelial dysfunction, whereas elevated levels of endocan and endoglin are indicative of elevated vascular inflammation. Increased concentrations of markers such as angiopoietin, E-selectin, P-selectin, ICAM-1, and VCAM-1 suggest endothelial activation, while higher levels of fractalkine, galectin, HMGB1, and osteopontin reflect an ongoing inflammatory state. Immunological markers, including HMGB1, neopterin, and serum amyloid A, are significantly elevated, underscoring prolonged immune activation associated with severe COVID-19. Elevated levels of matrix metalloproteinases (MMPs) and soluble urokinase plasminogen activator receptor (SuPAR) highlight tissue remodeling and fibrinolytic imbalance related to vascular injury. Additionally, increases in soluble fms-like tyrosine kinase-1 (sFlt-1) and pentraxin reflect inflammatory pathways that exacerbate endothelial dysfunction. Elevated levels of syndecan-1 reflect endothelial glycocalyx degradation and impaired endothelial barrier integrity. Increased von Willebrand factor (vWF) indicates endothelial activation and injury with a prothrombotic shift. Elevated surfactant protein D (SP-D) is a marker of pulmonary epithelial injury and disruption of the alveolar-capillary interface. Other biomarkers, such as the receptor for advanced glycation end products (RAGE) and MR-proADM, signal oxidative stress and endothelial damage. Collectively, these biomarkers emphasize the extensive vascular and endothelial impairment in COVID-19, suggesting their utility as diagnostic tools and potential targets for therapeutic intervention against the systemic effects of the disease. This review advocates for the integration of these biomarkers into standard monitoring and treatment protocols for COVID-19, thereby enhancing personalized care. Furthermore, our analysis underscores the necessity for additional research into the roles of these biomarkers in other endothelial disorders, ultimately contributing to a more nuanced approach to managing viral infections characterized by vascular complications.

PMID 42256874
阅读全文 →
PubMedNAR molecular medicine2026-06-04

Aptamer-mediated modulation of PAI-1 function reveals a novel mechanism for restoring fibrinolytic balance.

Matthews Alicia A, Breitman Adi A, Fortenberry Yolanda M YM

Plasminogen activator inhibitor-1 (PAI-1) is the principal regulator of fibrinolysis, acting by inhibiting tissue-type and urokinase-type plasminogen activators (tPA/uPA). Dysregulated PAI-1 activity contributes to diverse pathologies, including cancer, cardiovascular disease, and fibrosis, underscoring its therapeutic potential. We previously identified R10-4, an RNA aptamer that attenuates PAI-1's antiproteolytic activity against tPA by destabilizing covalent complex formation. To elucidate its inhibitory mechanism, we combined plasminogen activation assays with in silico modeling to map residue-level interactions. Systematic truncation of R10-4 revealed two regions critical for inhibition: (i) the reactive center loop, encompassing the s5A strand, and (ii) the vitronectin-binding domain. Removal of 17 nucleotides from the 3' end disrupted aptamer engagement, significantly altering R10-4's inhibitory activity. These findings define the structural basis for R10-4 modulation of PAI-1 function, revealing a novel aptamer-mediated mechanism of inhibition. By targeting key functional domains, R10-4 emerges as a promising prototype therapeutic for correcting fibrinolytic dysregulation in thrombotic and fibrotic disease.

PMID 42238354
阅读全文 →
PubMedMolecular therapy : the journal of the American Society of Gene Therapy2026-06-04

Directing fratricide within T cell products using an anti-uPAR chimeric antigen receptor to drive the production of potent therapeutic cells.

Sarko Lauren L, Givand David D, Rattin Brendan B, Shepley Claire C et al.

Cell therapy manufacturing of primary T cells often results in heterogeneous cell populations within a final product, with many cells lacking desired receptor expression or exhausted and other dysfunctional phenotypes. Here, we design a novel cell-intrinsic strategy to genetically reprogram primary human T cells to autonomously detect and eliminate dysfunctional cells. This integrated detection and elimination process, known as directed fratricide, is programmed via nonviral CRISPR genome-editing to eliminate the T cell receptor (TCR) alpha chain (TRAC gene knockout) and integrate a chimeric antigen receptor (CAR) against the urokinase-type plasminogen activator receptor (uPAR), also known as CD87. Within these cell products, strong T cell stimulation or activation during manufacturing causes a small subset of cells to express uPAR, which triggers CAR-mediated killing within the product. This fratricide induces proliferation in the desired cells and destroys undesired cells, a process that could be modeled computationally and controlled robustly via supplements to the culture media. The strategy enabled enrichment of anti-uPAR and anti-GD2 CAR T cell products up to ≥99% CAR+/TCR-, favoring a memory-like phenotype. Understanding growth dynamics among T cell subsets and reprogramming them via CRISPR could accelerate the biomanufacturing of potent cell products without extensive selection methods.

PMID 42237538
阅读全文 →
PubMedClinical & experimental metastasis2026-06-03

Modeling the role of urokinase-type plasminogen activator, uPA, and circulating cancer-associated fibroblasts (cCAFs) in breast cancer cell extravasation.

Spartz Angela A, Schmidt Susan S, Mohamed Fazila F, Troness Benjamin B et al.

Circulating Cancer-Associated Fibroblasts (cCAFs) have been identified in circulating tumor cell clusters from all stages of disease progression in breast cancer patients. We have shown that CAFs promote lung metastases in the mouse tail vein model when they are clustered with triple negative breast cancer (TNBC) MDA-MB231 cells. Following on this observation, we saw that MDA-MB231-luciferase labeled cells persist at higher levels when present in CAF23/MDA-MB231 co-clusters compared to MDA-MB231 mono-clusters within the first 3 days after tail vein injection. This prompted us to investigate whether CAFs aid cancer cell extravasation from capillary venules into the lung parenchyma, which would impart better survival and faster seeding of metastases. Ex vivo lung extravasation assays showed that within the first 8-24 h after tail vein injection, more cells from CAF23/MDA-MB231 co-clusters extravasated than cells from MDA-MB231 mono-clusters. Using in vitro endothelial binding assays, we determined that CAF/TNBC co-clusters bind to HUVEC endothelial cells better than TNBC mono-clusters. Single-Cell RNA sequencing identified several genes in the fibrinolysis pathway whose expression increases in TNBC cells when they are clustered with CAFs. One of these genes is PLAU, which encodes the urokinase-type plasminogen activator, uPA. siRNA knockdown of PLAU decreased in vitro TNBC-endothelial cell interactions and ex vivo extravasation of MDA-MB231 mono-clusters, revealing a potential role for CAF-induced factors expressed in TNBC cells, such as uPA/PLAU, in breast cancer cell extravasation. Our data helps to define the role of CAFs in breast cancer extravasation and highlights the importance of our previous work showing that CAFs promote tumor cell dissemination and metastasis.

PMID 42234219
阅读全文 →
PubMedScience advances2026-05-29

Hepatitis C virus infection dynamics, treatment, and lipid nanoparticle-mediated infection in humanized liver chimeric mouse models.

Park Seung Bum SB, Sánchez-Meza Jaime J, Umarova Regina R, Shields Justin J et al.

A major challenge in hepatitis C virus (HCV) research is the lack of an in vivo model that supports robust infection, antiviral testing, and vaccine development. The humanized liver chimeric mouse models support high-level viremia from various HCV sources, although they lack an immune system. Here, we used Fah-/-/Rag2-/-/Il2rg-/- (FRG) and urokinase-type plasminogen activator-severe combined immunodeficiency (uPA-SCID) mice engrafted with primary human hepatocytes to investigate HCV infection dynamics and evaluate lipid nanoparticle (LNP)-mediated delivery of full-length HCV RNA. Mice were inoculated with HCV-positive chimpanzee serum or LNP-encapsulated HCV RNA of various genotypes and developed viremia reaching 108 copies per milliliter. RNA-LNP-mediated infection mirrored serum-derived infection that was transmissible to naïve mice. Glecaprevir/pibrentasvir cleared viremia, and treated mice could be reinfected. The proportion of antibody-free HCV RNA in human serum correlated with infectivity. These findings demonstrate the utility of this model for studying HCV infection and treatment and highlight LNP-based RNA delivery as a scalable approach for generating standardized challenge inocula.

PMID 42213828
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多urokinase